设为首页 |  加入收藏
首页期刊介绍编委会投稿须知通知公告刊登文章继续教育园地协办单位联系我们广告合作
公告栏:
瑞格列奈联合太子参降糖方治疗112例NIDDM的疗效观察
作者:黄家娣  刘地广  杜顺颜  童新  叶健敏 
单位:佛山市顺德区陈村社区卫生服务中心, 广东 佛山 528000
关键词:2型糖尿病 瑞格列奈 太子参降糖方 二甲双胍 
中图分类号:R969.4
文献标志码:
出版年,卷(期):页码:2017,27(1):37-39,
收稿日期:2016-4-10
摘要:
目的 探讨瑞格列奈联合自拟太子参降糖方治疗2型糖尿病(非肥胖型,NIDDM)患者的疗效与临床意义。方法 选择本社区新确诊或服用瑞格列奈的NIDDM患者112例,按档案号奇偶数分为AB两组,A组54例:服用低剂量瑞格列奈治疗;B组58例:服用低剂量瑞格列奈联合太子参降糖方治疗。两组患者血糖控制不佳时从低剂量开始加用二甲双胍片。研究前检查患者临床症状、体质指数(BMI)、血压(SBP/DBP);检测空腹血糖(FPG)、非空腹血糖(NFPG)、糖化血红蛋白(HbA1C)、胰岛素抵抗指数(HOMA-IR)、总胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)、尿白蛋白/肌酐比值(ACR)、尿白蛋白排泄率(MALB);记录合并疾病的相关情况。分别在治疗12周和24周后复查上述各项指标并进行统计学分析。结果 治疗12周后,B组FPG、HbA1C、HOMA-IR、LDL-C、MALB、ACR均较A组低,24周后降低明显,差异有统计学意义(P<0.05);B组的BMI及HDL-C较A组高,差异有统计学意义(P<0.05);其他项目两组比较,差异无统计学意义(P>0.05)。结论 瑞格列奈联合太子参降糖方治疗NIDDM,比单用瑞格列奈效果好,可有效改善糖尿病患者的临床症状和相关指标。
OBJECTIVE The research is to investigate the efficacy and clinical significance of repaglinide in combination with Radix Pseudostellariae Jiangtangfang in treating type 2 diabetics (non-obese, NIDDM). METHODS Choose from the community 112 NIDDM patients who were newly diagnosed or taking repaglinide, and divide them into two groups according to the parity number of their archives as group A and B. Group A, including 54 samples, taked low-dose repaglinide in the treatment. Group B, including 58 samples, taked repaglinide in combination with Radix Pseudostellariae Jiangtangfang in the treatment. The patients from 2 groups begin to take metformin tablets when they failed to keep their blood glucose under control. Before the research, it was required to inspect and record the patients' clinical symptoms including body mass index (BMI), blood pressure (SBP/DBP), fasting blood glucose (FPG), non-fasting blood glucose (NFPG), glycosylated hemoglobin (HbA1C), insulin resistance index (HOMA-IR), total cholesterol (TC), Triglyceride (TG), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C), urinary albumin/creatinine ratio (ACR) and urinary albumin excretion rate (MALB). Record and consolidate the disease-related conditions continually. Finally, keep track of the indicators above and performing statistical analysis upon week 12 and 24 respectively. RESULTS With 12 weeks of treatment, the clinical factors of FPG、HbA1C、HOMA-IR、LDL-C、MALB、ACR of the patients in group B were lower than those of the patients in group A, and the reduction become obviously after 24 weeks of treatment and the difference was statistically significant(P<0.05), while the clinical factors of BMI and HDL-C of the patients in group B were higher than those of the patients in group A and the difference is statistically significant (P<0.05). And there was no statistically significant difference while comparing the two groups regarding other clinical factors (P<0.05). CONCLUSION Use of the combination of repaglinide and Radix Pseudostellariae Jiangtangfang in the treatment of NIDDM has the effectively positive effect on the clinical symptoms of diabetics and the indicators.
基金项目:
作者简介:
黄家娣,副主任药师,研究方向:药物管理学与临床药学,Tel:13118828733,E-mail:emy163@163.com
通讯作者:
参考文献:
[1] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中华糖尿病杂志,2014,6(7):447-460
[2] 王彩虹.利拉鲁肽治疗超重的2型糖尿病24例临床观察[J].今日药学,2014,24(1):60-63.
[3] 陈新谦,金有豫,汤光.新编药物学[M].第17版.北京:人民卫生出版社,2011:656-660.
[4] 中国国家处方集编委会.中国国家处方集[M].北京:中国军医出版社,2010:269-271.
[5] 杨薇,黎小妍,钱兴国,等.磺脲类联合他汀类药物和阿司匹林对2型糖尿病患者心血管并发症的预防作用[J].广东医学,2013,34(18):2868-2870.
[6] 路亚娥, 熊鹏,候杰军,等.降糖方配合西药治疗老年糖尿病30例[J].陕西中医,2012,22(10):1334-1336.
[7] 刘会民,赵敏杰.太子参临床应用及研究进展[J].中国医院用药评价与分析,2015,15(3):430-432.
[8] 徐先祥,黄玉香,夏伦祝,等.太子参多糖对糖尿病小鼠抗氧化能力与胰腺病理的影响[J].食品工业科技,2012,33(24):392-393.
[9] 李天虹,冠正杰,张苏,等.加味参芪地黄汤治疗气阴两虚型2型糖尿病66例[J].陕西中医,2010,31(8):1019-1022.
[10] 周辉林.中药降糖3号合二甲双胍治疗2型糖尿病32例[J].中国中医药现代远程教育,2014,12(24):64-65.
[11] 陈刚毅,李显红,林育,等.活血祛痰方对糖尿病肾病大鼠肾脏转化生长因子-β和Smad7表达的影响[J].广东医学,2014,35(23):3636-3638.
[12] 孔宪兰,王式云.太子参降糖方治疗Ⅱ型糖尿病33例[J].光明中医,2000,15(89):2728.
[13] 龚祝南,戴岳,马辉,等. 8个不同产地太子参对脾虚及免疫功能的影响[J].中药材,2001,24(4):281-282.
[14] 曾龙驿.英国前瞻性糖尿病研究(UKPDS)解毒[J].中国卒中杂志,2007,2(7):639-640.
[15] 谭敏琪.2型糖尿病患者社区治疗中应用二甲双胍的效果分析[J].今日药学,2015,25(1):49-50.
[16] 程桦.糖尿病治疗进展[J].广东医学,2008,29(2):167-169.
服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
 
友情链接  
广东今日药学杂志社有限公司   地址:广州市东风东路753号东塔7楼702
电话:020-37886325       邮箱:jinriyaoxue@163.com
本系统由北京博思汇文数字科技有限公司设计开发 技术服务电话:400-921-9838
粤ICP备20054928号

粤公网安备 44010402002138号

您是第 165169 位访问者